About: Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody
Creator	Sutton, Troy Subbarao, Kanta Vogel, Leatrice Gretebeck, Lisa Minai, Mahnaz Orandle, Marlene Lamirande, Elaine Bock, Kevin Houser, Katherine Kuhn, Jens Moore, Ian Broadbent, Andrew
Source	Medline; PMC
abstract	The Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic betacoronavirus that was first detected in humans in 2012 as a cause of severe acute respiratory disease. As of July 28, 2017, there have been 2,040 confirmed cases with 712 reported deaths. While many infections have been fatal, there have also been a large number of mild or asymptomatic cases discovered through monitoring and contact tracing. New Zealand white rabbits are a possible model for asymptomatic infection with MERS-CoV. In order to discover more about non-lethal infections and to learn whether a single infection with MERS-CoV would protect against reinfection, we inoculated rabbits with MERS-CoV and monitored the antibody and inflammatory response. Following intranasal infection, rabbits developed a transient dose-dependent pulmonary infection with moderately high levels of viral RNA, viral antigen, and perivascular inflammation in multiple lung lobes that was not associated with clinical signs. The rabbits developed antibodies against viral proteins that lacked neutralizing activity and the animals were not protected from reinfection. In fact, reinfection resulted in enhanced pulmonary inflammation, without an associated increase in viral RNA titers. Interestingly, passive transfer of serum from previously infected rabbits to naïve rabbits was associated with enhanced inflammation upon infection. We further found this inflammation was accompanied by increased recruitment of complement proteins compared to primary infection. However, reinfection elicited neutralizing antibodies that protected rabbits from subsequent viral challenge. Our data from the rabbit model suggests that people exposed to MERS-CoV who fail to develop a neutralizing antibody response, or persons whose neutralizing antibody titers have waned, may be at risk for severe lung disease on re-exposure to MERS-CoV.
has issue date	2017-08-17(xsd:dateTime)
bibo:doi	10.1371/journal.ppat.1006565
bibo:pmid	28817732
has license	cc0
sha1sum (hex)	555a36d1c3822baa8b6a2612b86ed5df5b1dbf7c
schema:url	https://doi.org/10.1371/journal.ppat.1006565
resource representing a document's title	Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody
has PubMed Central identifier	PMC5574614
has PubMed identifier	28817732
schema:publication	PLoS Pathog
resource representing a document's body	covid:555a36d1c3822baa8b6a2612b86ed5df5b1dbf7c#body_text
is schema:about of	named entity 'fail' named entity 'inflammation' named entity 'Following' named entity 'large number' named entity 'model' named entity 'multiple' named entity 'activity' named entity 'zoonotic' named entity 'rabbits' named entity 'enhanced' named entity 'inoculated' covid:arg/555a36d1c3822baa8b6a2612b86ed5df5b1dbf7c named entity 'data' named entity '2017' named entity 'infected' named entity 'neutralizing antibody' named entity 'animals' named entity 'antibodies' named entity 'cases' named entity 'infections' named entity 'MERS-CoV' named entity 'coronavirus' named entity 'New Zealand' named entity 'viral' named entity 'perivascular' named entity 'neutralizing antibody' named entity 'zoonotic' named entity 'respiratory disease' named entity 'inflammatory response' named entity 'MERS-CoV' named entity 'infection' named entity 'antigen' named entity 'inflammation' named entity 'dose-dependent' named entity 'lung disease' named entity 'viral RNA' named entity 'inoculated' named entity 'clinical signs' named entity 'New Zealand' named entity 'RNA' named entity 'virus' named entity 'spike protein' named entity 'complement cascade' named entity 'CD71' named entity 'non-human primates' named entity 'virus' named entity 'coronavirus' named entity 'complement proteins' named entity 'serum' named entity 'eosinophils' named entity 'antibody' named entity 'immune response' named entity 'Fc receptors' named entity 'recombinant' named entity 'infection' named entity 'secondary infection' named entity 'infection' named entity 'immune responses' named entity 'antibody-dependent enhancement' named entity 'FIPV' named entity 'antibodies' named entity 'SARS-CoV' named entity 'MERS' named entity 'antibodies' named entity 'bronchiolitis' named entity 'lung tissue' named entity 'IgG' named entity 'inflammation' named entity 'DPP4' named entity 'complement activation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software